Funded Biotechnology Startups in Spain
Barcelona accounts for more than half of the 50 most recently funded biotechnology companies in Spain, with standout rounds including Splice Bio's $135M Se…
Barcelona accounts for more than half of the 50 most recently funded biotechnology companies in Spain, with standout rounds including Splice Bio's $135M Series B in June 2025 — the largest disclosed raise in the dataset — alongside Integra Therapeutics' $13M Seed in September 2025 and Minoryx Therapeutics' $31M round in July 2025. Other Catalonia-based names such as Seqera ($26M Series B, May 2025) and Aortyx ($16M Series A, June 2025) reflect the region's activity across multiple stages.
Madrid and Valencia each anchor a secondary cluster. SYLENTIS ($25M, July 2025), Amadix ($16M, February 2025), and Cocoon Bioscience ($16M, March 2023) represent the Madrid contingent; ARTHEx Biotech ($41M Series B, September 2025) and Highlight Therapeutics ($18M, September 2025) lead Valencia. Round stage labeling skews heavily toward "Series Unknown," and at least 8 of the 50 entries carry undisclosed amounts. Three rounds — Minoryx Therapeutics, Oryzon Genomics SA, and SYLENTIS — all closed on July 10, 2025, indicating either coordinated announcement timing or a shared funding mechanism.
Most recent rounds
50 shownRelated listings
Frequently asked
What are the largest disclosed funding rounds among Spanish biotech companies in this data?
Splice Bio leads with a $135M Series B closed in Barcelona in June 2025. Atrys Health raised $76M in a post-IPO equity round in June 2022, and ARTHEx Biotech closed a $41M Series B in Valencia in September 2025. Minoryx Therapeutics ($31M, July 2025) and Seqera ($26M Series B, May 2025) round out the top five disclosed amounts.
Which city or region has the highest concentration of funded biotech startups in Spain?
Barcelona and the broader Catalonia region account for more than half of the 50 companies in this dataset, spanning early-stage names like FreeOx Biotech and Connecta Therapeutics through growth-stage companies like Splice Bio and Seqera. Madrid is the next-largest cluster with five companies — including SYLENTIS, Amadix, and Cocoon Bioscience — followed by Valencia with four.
What round stages are most common among recently funded Spanish biotech companies?
"Series Unknown" is the most frequently used stage designation across these 50 rows, covering a wide range of disclosed amounts from $550K (Onena Medicines) to $31M (Minoryx Therapeutics). Seed rounds are the second most common stage, appearing in 12 entries. The three Series B rounds — Splice Bio, ARTHEx Biotech, and Seqera — collectively represent the largest disclosed amounts in the dataset.
Are there any notable clustering patterns in when these rounds closed?
Three companies — Minoryx Therapeutics ($31M), Oryzon Genomics SA ($16M), and SYLENTIS ($25M) — all announced rounds on July 10, 2025. ARTHEx Biotech and Highlight Therapeutics both closed on September 17, 2025. The 17 most recent rounds in the dataset all fall between January 2025 and October 2025.
What therapeutic and technology areas appear most frequently among these recently funded companies?
RNA-targeting and splice-modulation platforms appear multiple times: Splice Bio, ARTHEx Biotech, and SYLENTIS all operate in this space. Diagnostics and early detection are represented by Universal Diagnostics (Seville, $21M), Amadix (Madrid, $16M), and Onalabs Inno-hub (Barcelona, $2M). Neuroscience-focused companies include INBRAIN Neuroelectronics ($5M), Gate2Brain ($3M), and Oniria Therapeutics ($1M), all headquartered in Barcelona.
How many companies in this dataset have undisclosed funding amounts, and what is the disclosed range?
Eight of the 50 entries list undisclosed amounts: Trovant Technology, IMIDomics, cofling, levprot, Alice Biometrics, Qubiotech, Nuage Therapeutics, and Imotion Analytics. Among the 42 with disclosed figures, the range runs from $10K (Rethink Medical, Barcelona) to $135M (Splice Bio, Barcelona).
Know which startups just got funded. Every week.
Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.
Free. Sent every Monday. Unsubscribe anytime.